Breast Neoplasm
Conditions
Keywords
Breast cancer
Brief summary
The primary objectives of the study are to evaluate the feasibility and toxicity of treatment with 12 weeks of Adriamycin with daily oral Cytoxan with G-CSF support followed by 12 weeks of Taxol. Feasibility will be assessed by comparing the delivered dose intensity of each drug to the delivered dose intensity in previous trials. Toxicity will be assessed by comparing the incidence and severity of toxicity with these drugs to previous trials using these drugs in the same combination. We hypothesize metronomic, dose dense treatment as given in this study will be less toxic and more effective than historical regimens using the same drugs in a less metronomic, dose dense manner.
Detailed description
The systemic cancer treatments used in this study (Adriamycin, Cytoxan and Taxol) are all delivered in a dose dense, metronomic manner (weekly or daily). It is our hypothesis that dose dense treatment will result in optimum delivered dose intensity while minimizing toxicity. We will test these hypotheses by comparing the delivered dose intensity of the drugs to the delivered dose intensity of standard regimens. We will also compare time to relapse, survival and toxicity of this treatment to historic, standard regimens.
Interventions
DRUGPaclitaxel
80 mg/m2 IV for 12 weeks following completion of doxorubicin and cyclophosphamide
DRUGDoxorubicin
24 mg/m2 IV weekly x 12
DRUGCyclophosphamide
60 mg/m2 PO daily for 12 weeks
DRUGG-CSF
5 mcg per kg subcutaneously days 2 - 7 during doxorubicin and cyclophosphamide for 12 weeks
Sponsors
Amgen
Bristol-Myers Squibb
University of Washington
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient must have a histologically confirmed diagnosis of primary breast carcinoma that has been surgically resected. (This regimen is not intended for neoadjuvant treatment.) * The attending physician must judge the patient to be an appropriate candidate for Adriamycin based adjuvant chemotherapy. Appropriate candidates generally include those with stage II or III breast cancer. The individual attending physician, however, should make the decision. * Tumor HER-2/neu expression must be determined prior to study enrollment. Assessment may be by fluorescence in situ hybridization (FISH) assay or by immunocytochemistry (ICC). If determination is intermediate by immunocytochemistry, FISH must be performed. Protocol therapy is determined by HER-2/neu result. * Patient must be at least 18. * The patient must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines. * Pre-study hematologic values required for entry onto trial are: WBC greater than= 4,000/mm3, ANC greater than= 1,500/mm3 and platelets greater than= 100,000/mm3.
Exclusion criteria
* Patients with significant renal dysfunction (creatinine greater than 1.5 x institutional upper limit of normal (IULN)) or hepatic dysfunction (bilirubin greater than IULN; transaminases greater than 2.5 x IULN) are not eligible. * Except for the following, no prior malignancy is allowed: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient has been disease free for 5 years. * Patients with clinically apparent cardiac disease, or history of same, are not eligible. Patients who are \> 60 years of age or who have a history of hypertension must have a MUGA prior to enrollment. LVEF must be normal. * Patients who have received prior chemotherapy or radiotherapy are not eligible. * Patients who are pregnant or breastfeeding are not eligible. Women of child bearing potential must have a serum pregnancy test that is negative and agree to practice adequate contraception. * Patients with active infection are not eligible. * Patients who are known to be infected with HIV, hepatitis B or hepatitis C are not eligible. Testing is not required unless there is a high index of clinical suspicion. * Patients suffering from psychiatric impairment are not eligible. * Patients with known hypersensitivity to trimethoprim or sulfonamides are not eligible.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Delivered dose intensity | 24 weeks |
| Toxicity | 24 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Time to treatment failure | 7 years |
| Overall survival | 7 years |
Countries
United States
Outcome results
None listed